KEGG   DRUG: Tafasitamab
Entry
D11601                      Drug                                   

Name
Tafasitamab (USAN/INN);
Tafasitamab-cxix;
Monjuvi (TN);
Minjuvi (TN)
Product
Formula
C6550H10092N1724O2048S52
Exact mass
147332.4026
Mol weight
147423.9175
Sequence
(Heavy chain)
EVQLVESGGG LVKPGGSLKL SCAASGYTFT SYVMHWVRQA PGKGLEWIGY INPYNDGTKY
NEKFQGRVTI SSDKSISTAY MELSSLRSED TAMYYCARGT YYYGTRVFDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
GPDVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF
NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK ALPAPEEKTI SKTKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIVMTQSPAT LSLSPGERAT LSCRSSKSLQ NVNGNTYLYW FQQKPGQSPQ LLIYRMSNLN
SGVPDRFSGS GSGTEFTLTI SSLEPEDFAV YYCMQHLEYP ITFGAGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L219, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'219, H'265-H'325, H'371-H'429, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Remark
ATC code: L01XC35
Product: D11601<US>
Efficacy
Antineoplastic, Anti-CD19 antibody
  Disease
Diffuse large B-cell lymphoma (CD19-directed) [DS:H02434]
Comment
Monoclonal antibody
Treatment of CD19-positive hematologic malignancies
Target
CD19 [HSA:930] [KO:K06465]
  Pathway
hsa04151  PI3K-Akt signaling pathway
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC35 Tafasitamab
      D11601  Tafasitamab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Tafasitamab
    D11601  Tafasitamab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11601  Tafasitamab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11601
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11601
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11601
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11601
Other DBs
CAS: 1422527-84-1
PubChem: 405226468
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system